DRIO vs OMCL

For growth investors, Omnicell, Inc.

(OMCL) is the stronger pick with 6. 5% revenue growth year-over-year, versus -17. 3% for DarioHealth Corp. (DRIO). DarioHealth Corp. (DRIO) offers the better valuation at 6. 6x trailing P/E, making it the more compelling value choice. Analysts rate DarioHealth Corp. (DRIO) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, DarioHealth Corp.

(DRIO) is the cheapest at 6. 6x versus Omnicell, Inc. at 978. 1x.

Over the past 5 years, Omnicell, Inc.

(OMCL) delivered a total return of -69. 4%, compared to -97. 8% for DarioHealth Corp. (DRIO). Over 10 years, the gap is even starker: OMCL returned +36. 3% versus DRIO's -99. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), DarioHealth Corp.

(DRIO) is the lower-risk stock at 0. 26β versus Omnicell, Inc. 's 1. 34β — meaning OMCL is approximately 407% more volatile than DRIO relative to the S&P 500. On balance sheet safety, Omnicell, Inc. (OMCL) carries a lower debt/equity ratio of 17% versus 47% for DarioHealth Corp. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Omnicell, Inc.

(OMCL) is pulling ahead at 6. 5% versus -17. 3% for DarioHealth Corp. (DRIO). On earnings-per-share growth, the picture is similar: DarioHealth Corp. grew EPS 267. 6% year-over-year, compared to -83. 6% for Omnicell, Inc.. Over a 3-year CAGR, OMCL leads at -2. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

DarioHealth Corp.

(DRIO) is the more profitable company, earning 276. 1% net margin versus 0. 2% for Omnicell, Inc. — meaning it keeps 276. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: OMCL leads at 0. 4% versus -163. 9% for DRIO. At the gross margin level — before operating expenses — DRIO leads at 56. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for DRIO: 96.

9% to $16. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, DarioHealth Corp.

(DRIO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 26)). Both have compounded well over 10 years (DRIO: -99. 6%, OMCL: +36. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: DRIO is a small-cap deep-value stock; OMCL is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.